Compare Bristol-Myers Squibb Co (BMY) vs Gemini Space Station Inc (GEMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Gemini Space Station Inc — how do they compare? Bristol-Myers Squibb Co trades at $58.51 (market cap $116.30B), while Gemini Space Station Inc trades at $4.7 (market cap $548.72M). The key difference: Bristol-Myers Squibb Co is far larger — about 211.9× Gemini Space Station Inc's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Gemini Space Station Inc pays none. Which is the better fit depends on your goals.
| BMY | GEMI | |
|---|---|---|
Market Cap | $116.30B | $548.72M |
Sector | Health | Technology |
52-Week High | $62.37 | $32.52 |
52-Week Low | $42.60 | $3.91 |
Enterprise Value | $152.24B | $538.70M |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
GEMI trades at $4.25, down 1.39% on the day, amid a bearish technical signal and weak fundamentals. The company reported significant losses, with a net income margin of -278.9% in 2025, and has missed earnings expectations for three consecutive quarters. Recent news includes a class action lawsuit and a $100 million investment from Winklevoss Capital, creating mixed sentiment.
The outlook remains challenging due to persistent unprofitability and legal risks, though analyst consensus suggests moderate upside with a $5.88 price target. Investment opportunity hinges on the company's ability to leverage new capital for growth, but high execution and regulatory risks warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Gemini Space Station Inc
Gemini Space Station Inc is the parent company of the Gemini crypto ecosystem, founded by Cameron and Tyler Winklevoss. It operates as a regulated digital asset exchange and custodian, providing a platform for individuals and institutions to trade, store, and stake cryptocurrencies while serving as a trusted bridge between legacy finance and the decentralized web.
Read more on GEMI →
